Cagrilintide
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for obesity treatment. It is being studied both as monotherapy and in combination with semaglutide (CagriSema) in the Phase 3 REDEFINE program.
Cagrilintide is a synthetic long-acting amylin receptor agonist developed by Novo Nordisk for the treatment of obesity and overweight. As an acylated analog of the pancreatic hormone amylin, cagrilintide slows gastric emptying, promotes satiety, and suppresses glucagon secretion.
Overview
Cagrilintide represents a significant advance over pramlintide, the only previously approved amylin analog, by extending the dosing interval from three times daily to once weekly through fatty acid acylation that promotes albumin binding. Amylin is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to meals. It complements insulin's actions by slowing gastric emptying, promoting satiety through hypothalamic signaling, and suppressing inappropriate postprandial glucagon secretion.
The combination of cagrilintide with semaglutide (CagriSema) targets two distinct but complementary appetite regulation pathways. While GLP-1 receptor agonism (semaglutide) and amylin receptor agonism (cagrilintide) both promote satiety, they do so through partially independent neural circuits in the brainstem and hypothalamus. This mechanistic complementarity is hypothesized to produce additive or synergistic weight loss effects.
Mechanism of Action
Cagrilintide activates amylin receptors (calcitonin receptor/RAMP heterodimers) through several coordinated physiological mechanisms:
Gastric Emptying: Cagrilintide slows gastric emptying, reducing the rate of nutrient absorption and stabilizing postprandial glucose excursions. This effect contributes to both glycemic control and satiety.
Central Satiety Signaling: Amylin receptors in the area postrema and nucleus of the solitary tract in the brainstem mediate satiety signals that reduce meal size and food intake. Cagrilintide's prolonged receptor activation provides sustained appetite suppression throughout the dosing interval.
Glucagon Suppression: Cagrilintide suppresses inappropriate postprandial glucagon secretion from pancreatic alpha cells, complementing insulin's glucose-lowering effects and reducing hepatic glucose output.
Complementary Pathway to GLP-1: Unlike GLP-1 receptor agonists, amylin acts primarily through calcitonin receptor complexes (CTR/RAMP1, CTR/RAMP3). This distinct receptor pharmacology means cagrilintide and semaglutide engage different downstream signaling cascades, providing a rationale for combination therapy (CagriSema).
Reward Pathway Modulation: Emerging evidence suggests amylin receptor signaling may modulate dopaminergic reward pathways involved in hedonic eating, potentially reducing cravings and food-seeking behavior beyond simple satiety.
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Type 2 Diabetes
CagriSema is also under investigation for type 2 diabetes, where the combination of amylin- and GLP-1-mediated glucose control may provide superior HbA1c reduction alongside substantial weight loss. The dual mechanism targets both postprandial glucose excursions (via delayed gastric emptying and glucagon suppression) and fasting glucose (via improved insulin sensitivity from weight loss).
Cardiovascular Risk Factors
Across Phase 2 studies, cagrilintide and CagriSema produced improvements in cardiovascular risk markers including reductions in systolic blood pressure, triglycerides, and waist circumference, consistent with the degree of weight loss achieved.
Comparison to Related Compounds
| Parameter | Cagrilintide (2.4 mg) | Pramlintide (Symlin) | Amylin (endogenous) | CagriSema |
|---|---|---|---|---|
| Receptor target | Amylin receptors (CTR/RAMP) | Amylin receptors (CTR/RAMP) | Amylin receptors (CTR/RAMP) | Amylin + GLP-1 receptors |
| Dosing frequency | Once weekly | Three times daily (pre-meal) | Continuous (endogenous) | Once weekly |
| Half-life | ~160 hours (~4 days) | ~48 minutes | ~13 minutes | ~4 days (cagri) / ~7 days (sema) |
| Weight loss | ~10.8% (26 wk monotherapy) | ~1-2% | N/A | ~15.6% (32 wk) |
| Aggregation tendency | Minimal (engineered) | Minimal (Pro substitutions) | High (forms amyloid fibrils) | N/A |
| Development stage | Phase 3 (in CagriSema) | FDA-approved (diabetes) | Endogenous hormone | Phase 3 |
Cagrilintide vs. Pramlintide: Pramlintide (Symlin) is the only FDA-approved amylin analog, indicated as adjunct therapy for type 1 and type 2 diabetes. Pramlintide requires three-times-daily pre-meal injections due to its short half-life (~48 minutes), while cagrilintide's acylation enables once-weekly dosing. Pramlintide uses proline substitutions at positions 25, 28, and 29 to prevent amyloid fibril formation, while cagrilintide uses a different engineering approach with fatty acid acylation. The convenience advantage of weekly dosing makes cagrilintide more suitable for chronic weight management.
Cagrilintide vs. Amylin (Endogenous): Native amylin has a half-life of approximately 13 minutes and is prone to aggregation into amyloid fibrils, which is implicated in beta cell loss in type 2 diabetes. Cagrilintide overcomes both limitations through structural modifications that prevent aggregation and fatty acid acylation that extends the half-life to approximately 4 days.
CagriSema vs. Tirzepatide: CagriSema and tirzepatide represent different strategies for multi-pathway anti-obesity therapy. Tirzepatide combines GIP and GLP-1 receptor agonism in a single molecule, while CagriSema combines separate amylin and GLP-1 receptor agonists. Head-to-head Phase 3 trials are anticipated to compare these approaches directly.
Ongoing & Future Research
Several Phase 3 trials are actively investigating CagriSema:
-
REDEFINE-1 (NCT05567796): Pivotal Phase 3 trial evaluating CagriSema versus placebo in adults with obesity (BMI ≥30 or ≥27 with comorbidity) without type 2 diabetes. Randomized, double-blind design. Primary endpoints: percent change in body weight and proportion achieving ≥5% weight loss. Estimated enrollment: ~3,400 participants. Estimated completion: 2025.
-
REDEFINE-2 (NCT05394519): Phase 3 trial evaluating CagriSema in adults with overweight/obesity and type 2 diabetes. This trial addresses the dual indication of weight management and glycemic control.
-
REDEFINE-3 (NCT05813925): Phase 3 trial comparing CagriSema against tirzepatide and semaglutide alone. This head-to-head comparison will be critical for positioning CagriSema relative to approved incretin-based therapies.
-
REDEFINE-4 (NCT06024681): Phase 3 cardiovascular outcomes trial evaluating whether CagriSema reduces major adverse cardiovascular events in adults with obesity.
CagriSema Combination (Cagrilintide + Semaglutide 2.4 mg)
The Phase 2 trial of CagriSema evaluated the combination of cagrilintide 2.4 mg + semaglutide 2.4 mg versus each component alone in adults with overweight or obesity. At 32 weeks, CagriSema achieved mean weight loss of 15.6%, compared to 8.1% with cagrilintide alone and 5.1% with semaglutide alone (at an earlier stage of dose escalation). The additive effect supported the hypothesis that dual amylin/GLP-1 pathway engagement produces superior weight loss. Enebo LB et al. (2021) — Lancet 397, 971-984.
Cagrilintide Monotherapy
In Phase 2 dose-finding studies, cagrilintide monotherapy at doses up to 4.5 mg weekly produced dose-dependent weight loss of up to 10.8% over 26 weeks in adults with overweight or obesity. The weight loss was accompanied by improvements in waist circumference, fasting glucose, and lipid parameters. These results established cagrilintide as an effective anti-obesity agent in its own right, though the combination with semaglutide provides greater efficacy. Lau DCW et al. (2021) — Lancet 398, 2160-2172.
Safety Profile
Common adverse effects include gastrointestinal symptoms such as nausea (15-25%), vomiting, diarrhea, and decreased appetite, consistent with both amylin and GLP-1 receptor agonist classes. Injection site reactions (erythema, pruritus) have been reported at higher rates than with semaglutide alone, potentially related to the cagrilintide component. GI side effects are typically mild to moderate, most prevalent during dose escalation, and tend to diminish with continued treatment. Hypoglycemia risk is low when used without insulin or sulfonylureas. Heart rate increases of 1-3 bpm have been observed, consistent with the GLP-1 agonist class. The safety profile of CagriSema appears generally consistent with the known safety profiles of each component, with no unexpected synergistic toxicities identified in Phase 2.
Pharmacokinetic Profile
Cagrilintide — Pharmacokinetic Curve
Subcutaneous injection (once weekly)Quick Start
- Typical Dose
- 2.4mg weekly (after escalation)
- Frequency
- Once weekly, same day each week
- Route
- Subcutaneous injection (once weekly)
- Cycle Length
- Continuous long-term therapy
- Storage
- Lyophilized: -20°C frozen; Reconstituted: 2-8°C refrigerated, use within 30 days
Molecular Structure
- Formula
- C194H312N54O59S2
- Weight
- 4 Da
- Length
- 37 amino acids
- PubChem CID
- 171397054
- Exact Mass
- 4408.2582 Da
- LogP
- -12.5
- TPSA
- 1880 Ų
- H-Bond Donors
- 60
- H-Bond Acceptors
- 65
- Rotatable Bonds
- 137
- Complexity
- 10800
Identifiers (SMILES, InChI)
InChI=1S/C194H312N54O59S2/c1-19-100(10)151(184(298)233-128(78-98(6)7)189(303)248-75-49-60-137(248)190(304)247-74-48-59-136(247)182(296)243-155(107(17)255)187(301)232-127(86-143(201)262)173(287)238-150(99(8)9)183(297)210-88-146(265)218-129(90-249)176(290)230-126(85-142(200)261)175(289)244-156(108(18)256)191(305)246-73-46-57-134(246)157(202)271)239-181(295)135-58-47-72-245(135)147(266)89-211-161(275)120(79-109-50-36-34-37-51-109)225-171(285)123(82-139(197)258)228-172(286)124(83-140(198)259)229-177(291)130(91-250)235-178(292)131(92-251)234-170(284)122(81-111-87-207-95-212-111)227-164(278)114(56-45-71-209-194(205)206)221-168(282)119(77-97(4)5)224-169(283)121(80-110-52-38-35-39-53-110)226-166(280)116(65-68-149(269)270)219-158(272)101(11)213-167(281)118(76-96(2)3)223-163(277)113(55-44-70-208-193(203)204)220-165(279)115(63-66-138(196)257)222-186(300)153(105(15)253)240-159(273)102(12)214-179(293)132-93-308-309-94-133(180(294)231-125(84-141(199)260)174(288)242-152(104(14)252)185(299)215-103(13)160(274)241-154(106(16)254)188(302)237-132)236-162(276)112(54-42-43-69-195)216-145(264)67-64-117(192(306)307)217-144(263)61-40-32-30-28-26-24-22-20-21-23-25-27-29-31-33-41-62-148(267)268/h34-39,50-53,87,95-108,112-137,150-156,249-256H,19-33,40-49,54-86,88-94,195H2,1-18H3,(H2,196,257)(H2,197,258)(H2,198,259)(H2,199,260)(H2,200,261)(H2,201,262)(H2,202,271)(H,207,212)(H,210,297)(H,211,275)(H,213,281)(H,214,293)(H,215,299)(H,216,264)(H,217,263)(H,218,265)(H,219,272)(H,220,279)(H,221,282)(H,222,300)(H,223,277)(H,224,283)(H,225,285)(H,226,280)(H,227,278)(H,228,286)(H,229,291)(H,230,290)(H,231,294)(H,232,301)(H,233,298)(H,234,284)(H,235,292)(H,236,276)(H,237,302)(H,238,287)(H,239,295)(H,240,273)(H,241,274)(H,242,288)(H,243,296)(H,244,289)(H,267,268)(H,269,270)(H,306,307)(H4,203,204,208)(H4,205,206,209)/t100-,101+,102-,103-,104+,105+,106+,107-,108-,112-,113-,114-,115-,116-,117-,118+,119-,120-,121-,122-,123-,124-,125-,126+,127+,128+,129+,130-,131-,132-,133-,134+,135-,136+,137+,150+,151-,152-,153-,154-,155+,156+/m0/s1
LDERDVMBIYGIOI-IZVMHKDJSA-NResearch Indications
Weight Loss
Phase 3 trials demonstrate significant weight loss.
22.7% weight loss with CagriSema combination, surpassing existing therapies.
15.7% weight loss in diabetic patients with concurrent glycemic improvements.
Metabolic
2.2% HbA1c reduction with CagriSema versus semaglutide alone.
Amylin receptor activation enhances insulin sensitivity and glucose metabolism.
Appetite Control
Dual pathway satiety via amylin and calcitonin receptor activation.
Research Protocols
subcutaneous Injection
Long-acting amylin analog administered once weekly with dose doubling every 2 weeks.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Initiation | 0.6 mg | Once weekly | Weeks 1-2 |
| Escalation 1 | 1.2 mg | Once weekly | Weeks 3-4 |
| Escalation 2 | 2.4 mg | Once weekly | Weeks 5-6 |
| Maintenance | 4.5 mg | Once weekly | Weeks 7+(Cycle 12-16 weeks) |
Reconstitution Guide (5mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 1.67 mg/mL
- For 0.6 mg dose: draw 36 units (0.36 mL)
- For 1.2 mg dose: draw 72 units (0.72 mL)
- For 2.4 mg dose: draw 144 units (1.44 mL) — split into 2 injections
- For 4.5 mg dose: use multiple vials as needed
- Store reconstituted vial refrigerated at 2-8°C
Interactions
Peptide Interactions
The Phase 2 trial of CagriSema evaluated the combination of cagrilintide 2.4 mg + semaglutide 2.4 mg versus each component alone in adults with overweight or obesity. At 32 weeks, CagriSema achieved mean weight loss of 15.6%, compared to 8.1% with cagrilintide alone and 5.1% with semaglutide alon...
While GLP-1 receptor agonism (semaglutide) and amylin receptor agonism (cagrilintide) both promote satiety, they do so through partially independent neural circuits in the brainstem and hypothalamus.
It complements insulin's actions by slowing gastric emptying, promoting satiety through hypothalamic signaling, and suppressing inappropriate postprandial glucagon secretion.
The combination of cagrilintide with semaglutide (CagriSema) targets two distinct but complementary appetite regulation pathways.
What to Expect
What to Expect
Gastrointestinal adaptation; mild nausea possible during dose escalation
Early weight loss (2-5%); noticeable appetite reduction
Significant weight loss acceleration (10-15%); improved satiety signals
Peak efficacy (15-23% weight loss); sustained maintenance with continued therapy
Safety Profile
Common Side Effects
- Gastrointestinal effects (nausea, vomiting, diarrhea) during initial weeks
- Anti-cagrilintide antibodies develop in 46-73% but do not affect efficacy
- Only 57.3% achieved maximum 2.4mg dose in REDEFINE 1 trial
Contraindications
- Not recommended in pregnancy or breastfeeding
- Not yet commercially available (FDA approval expected Q1 2026)
Discontinue If
- Severe persistent nausea/vomiting preventing hydration
- Pancreatitis signs (severe abdominal pain radiating to back)
- Severe allergic reactions or anaphylaxis
- Significant injection site reactions or abscess formation
Quality Indicators
What to look for
- Pre-filled pen design when approved
- Pharmaceutical grade purity >98%
- Frozen storage stability at -20°C
- Extended stability over 7-day dosing interval
Caution
- Standard bacteriostatic water acceptable short-term but may degrade at neutral pH; optimal stability requires pH ~4.0
Red flags
- Fibril formation at improper pH—solution must remain clear
- Aggregation or precipitation indicates degradation
Frequently Asked Questions
References (7)
- [1]REDEFINE 1 Trial - Phase 3 Weight Loss (2025)
- [2]REDEFINE 2 Trial - Phase 3 Type 2 Diabetes (2025)
- [3]Phase 2 Type 2 Diabetes Combination Study (2023)
- [7]
- [4]
- [5]Lau, D. C. W. et al Once-weekly cagrilintide for weight management in people with overweight and obesity Lancet (2021)
- [6]Frias, J. P. et al Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with subcutaneous semaglutide 2.4 mg in type 2 diabetes Lancet (2023)
CagriSema (Cagrilintide + Semaglutide)
CagriSema is a fixed-ratio combination of cagrilintide (a long-acting amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist) developed by Novo Nordisk. The REDEFINE clinical trial program has demonstrated superior weight loss (~25% body weight) compared to either component alone through synergistic amylin-GLP-1 dual-action mechanisms.
Calcitonin Gene-Related Peptide (CGRP)
Calcitonin Gene-Related Peptide (CGRP) is a 37-amino-acid neuropeptide and the most potent endogenous vasodilator known. Existing as α-CGRP (neural) and β-CGRP (enteric) isoforms, it signals through the CLR/RAMP1 receptor complex and plays a central role in migraine pathophysiology, neurogenic inflammation, and cardiovascular protection.